

Special Issue

Research on Inherited Retinal Dystrophies

Message from the Guest Editors

Genes has decided to dedicate a Special Issue in 2022 to Inherited retinal dystrophies. Dr Vasiliki Kalatzis and I are pleased to work with you on this special issue dedicated to these challenging disorders. It is highly important to share our knowledge of these rare inherited retinal dystrophies that can appear “dark” for our colleagues in terms of clinical, pathophysiological and research aspects. The intent of the Special Issue is to simply describe the novel entities discovered and the advances made by the development of i) next generation sequencing, ii) pertinent cell models, such as iPSC-derived retinal organoids, and iii) novel therapies, ranging from pharmacological to molecular. We invite you to take part in this Special Issue with a scientific contribution. The manuscripts will, as always, be subjected to examination by specialized reviewers to guarantee their scientific acceptability.

Guest Editors

Prof. Dr. Isabelle Meunier

Hop Gui Chauillac, Ctr Reference Malad Sensorielles Genet, Institute for Neurosciences of Montpellier, University of Montpellier, INSERM, U1051, Montpellier, France

Dr. Vasiliki Kalatzis

INM, University of Montpellier, Inserm, Montpellier, France

Deadline for manuscript submissions

closed (25 February 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/89989

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))